

Marina Scarpelli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6613835/marina-scarpelli-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122
papers

1,430
citations

20
h-index

31
g-index

146
ext. papers

1,970
ext. citations

5.4
avg, IF

4.77
L-index

#	Paper	IF	Citations
122	Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles.. <i>Pathology Research and Practice</i> , 2021 , 229, 153737	3.4	
121	What's the future in uropathology. <i>Urologia</i> , 2021 , 88, 265-266	1.2	
120	Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. <i>European Urology Focus</i> , 2021 , 7, 955-963	5.1	3
119	Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. <i>Translational Andrology and Urology</i> , 2021 , 10, 1506-1520	2.3	7
118	Let us not forget about our past contributions to the field of prostatic neoplasms: To some extent what we value now was already there. <i>Pathology Research and Practice</i> , 2021 , 219, 153377	3.4	
117	Narrative review: update on immunotherapy and pathological features in patients with bladder cancer. <i>Translational Andrology and Urology</i> , 2021 , 10, 1521-1529	2.3	5
116	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. <i>Translational Andrology and Urology</i> , 2021 , 10, 1530-1540	2.3	0
115	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?-a narrative review. <i>Translational Andrology and Urology</i> , 2021 , 10, 1541-1552	2.3	2
114	Re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. <i>Eur Urol Focus</i> . In press. https://doi.org/10.1016/j.euf.2021.03.017 : Focus on Our Personal Recollections and Observations.	5.1	
113	Lesson from the COVID-19 pandemic: pathologists need to build their confidence on working in a digital microscopy environment. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 479, 227-229	5.1	2
112	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
111	RE: Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer, by Jones TD and Cheng L, https://doi.org/10.1016/j.urolonc.2020.12.007 (Low grade papillary intra-urothelial neoplasia). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 308-309	2.8	
110	Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. <i>Eur Urol</i> 2021;79:489-91. <i>European Urology</i> , 2021 , 79, e172-e173	10.2	1
109	The Coronavirus Disease 2019 (COVID-19) Pandemic's Impact on Social Interaction in Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2021 , 145, 1049-1050	5	
108	Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. <i>European Urology Oncology</i> , 2021 , 4, 331-333	6.7	3
107	Re: Alfonso Gñez de Liañ Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. <i>Eur Urol</i> 2020;77:269-76: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. <i>European Urology</i> , 2021 , 79, e17-e19	10.2	1
106	Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review. <i>European Urology Oncology</i> , 2021 , 4, 558-569	6.7	3

105	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , 2021 , 13,	6.6	51
104	Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. <i>Cancers</i> , 2021 , 13,	6.6	12
103	Treating Prostate Cancer by Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	8
102	An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer. <i>Oncology Letters</i> , 2021 , 21, 267	2.6	
101	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. <i>Translational Andrology and Urology</i> , 2021 , 10, 1581-1587	2.3	0
100	Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Brödl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology	6.7	
99	Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2021.03.009 : Focus on Intraductal Carcinoma of the Prostate. <i>European Urology</i> , 2021 , 80, e81-e82	10.2	
98	Artificial intelligence and prostate cancer: Advances and challenges. <i>Urologia</i> , 2021 , 3915603211062409	1.2	0
97	Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. <i>Cells</i> , 2020 , 9,	7.9	26
96	From Undergraduate Medical School Student to Visible Pathologist. <i>Archives of Pathology and Laboratory Medicine</i> , 2020 , 144, 413-414	5	1
95	Urologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance. <i>European Urology</i> , 2020 , 78, 478-481	10.2	8
94	Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. <i>European Urology</i> , 2020 , 78, 114-116	10.2	3
93	Acne agminata in Crohn's disease: A diagnostic and therapeutic challenge case for dermatologists. <i>Dermatologic Therapy</i> , 2020 , 33, e13935	2.2	1
92	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. <i>Cells</i> , 2020 , 9,	7.9	2
91	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. <i>Cells</i> , 2020 , 9,	7.9	4
90	Renal Cell Carcinoma: genomic landscape and clinical implications. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020 , 5, 95-100	1.6	1
89	Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-cancer/ . <i>Eur Urol</i> 2019;76:871. <i>European Urology</i> , 2020 , 77, e122-e127	10.2	
88	Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. <i>Cells</i> , 2020 , 9,	7.9	8

87	Combining Radiotherapy with Immunocheckpoin Inhibitors or CAR-T in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020 , 21, 416-423	3	4
86	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020 , 21, 1664-1671	3	3
85	PD-L1 Inhibitors for the Treatment of Prostate Cancer. <i>Current Drug Targets</i> , 2020 , 21, 1558-1565	3	1
84	Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 231-243	3.8	14
83	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020 , 9,	7.9	25
82	Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC. <i>Journal of Clinical Pathology</i> , 2020 , 73, 695-696	3.9	11
81	Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. <i>Eur Urol</i> 2019;76:27-30: Morphologic Documentation from Didactic Cases of Large-format Histology. <i>European Urology</i> , 2020 , 77, e100-e102	10.2	
80	Prostate cancer pathology: What has changed in the last 5 years. <i>Urologia</i> , 2020 , 87, 3-10	1.2	3
79	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 207-217	3.8	4
78	Liquid biopsy in the clinical management of bladder cancer: current status and future developments. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 255-264	3.8	9
77	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 141-150	3.8	9
76	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , 2019 , 11,	6.6	11
75	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. <i>Therapeutic Advances in Urology</i> , 2019 , 11, 1756287218815372	3.2	6
74	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019 , 11,	6.6	21
73	Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>Eur Urol</i> 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?. <i>European Urology</i> , 2019 , 76, e69-e72	10.2	5
72	Microbiome and Cancers, With Focus on Genitourinary Tumors. <i>Frontiers in Oncology</i> , 2019 , 9, 178	5.3	10
71	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019 , 11,	6.6	20
70	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. <i>Cancers</i> , 2019 , 11,	6.6	15

69	PD-L1 assessment in urothelial carcinoma: a practical approach. <i>Annals of Translational Medicine</i> , 2019 , 7, 690	3.2	38
68	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. <i>Current Drug Metabolism</i> , 2019 , 20, 305-312	3.5	7
67	Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019 , 71, 189-190	4.4	1
66	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2019 , 12,	6.6	14
65	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 917-927	2.5	2
64	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. <i>Journal of Clinical Pathology</i> , 2019 , 72, 135-139	3.9	17
63	Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. <i>J Vasc Interv Radiol</i> 2018;29:589-97. <i>Eur Urol</i> 2018;74:525-6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization?. <i>European Urology</i> , 2019 , 75, e110-e113	10.2	3
62	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019 , 8,	7.9	20
61	Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Sparing in Radical Prostatectomy. <i>European Urology</i> , 2018 , 73, 978-980	10.2	1
60	Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 685-693	3.5	8
59	Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. <i>Frontiers in Oncology</i> , 2018 , 8, 221	5.3	18
58	Editorial Comment. <i>Journal of Urology</i> , 2018 , 199, 1486-1487	2.5	
57	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , 2018 , 14, 2559-2564	3.6	5
56	Re: Isabel Rauscher, Charlotte Düvel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. <i>Eur Urol</i> 2018;73:656-61. Clinical Significance of	10.2	3
55	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. <i>Cancer Treatment Reviews</i> , 2018 , 68, 80-85	14.4	18
54	Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors. <i>European Urology</i> , 2018 , 74, 521-522	10.2	21
53	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 645-655	3.8	13
52	A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay. <i>Familial Cancer</i> , 2018 , 17, 215-224	3	0

51	Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 1021-1028	3.8	6
50	The Identification of Immunological Biomarkers in Kidney Cancers. <i>Frontiers in Oncology</i> , 2018 , 8, 456	5.3	32
49	New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. <i>Frontiers in Oncology</i> , 2018 , 8, 653	5.3	39
48	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018 , 8, 397	5.3	15
47	Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 131, 1-6	7	5
46	Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers. <i>International Journal of Biological Markers</i> , 2018 , 33, 331-334	2.8	5
45	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. <i>World Journal of Urology</i> , 2017 , 35, 517-526	4	9
44	Tp53 and its potential therapeutic role as a target in bladder cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 401-414	6.4	24
43	Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. <i>Future Oncology</i> , 2017 , 13, 1105-1114	3.6	4
42	Biliary plastic stent does not influence the accuracy of endoscopic ultrasound-guided sampling of pancreatic head masses performed with core biopsy needles. <i>Digestive and Liver Disease</i> , 2017 , 49, 898-902	3.3	9
41	Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. <i>Eur Urol</i> 2017;71:790-807. <i>European Urology</i> , 2017 , 72, e139-e141	10.2	1
40	Pathology and molecular updates in tumors of the prostate: towards a personalized approach. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 781-789	3.8	7
39	Re: Kenneth A. Iczkowski Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. <i>Eur Urol</i> 2016;70:738-9; Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Considerations for standardizing predictive molecular pathology for cancer prognosis. <i>Expert</i>	10.2	2
38	<i>Review of Molecular Diagnostics</i> , 2017 , 17, 47-55	3.8	3
37	Prospects for precision therapy of bladder urothelial carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017 , 2, 261-274	1.6	1
36	Immunotherapy in genitourinary cancers: where are we going?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017 , 2, 73-78	1.6	2
35	Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. <i>Archives of Pathology and Laboratory Medicine</i> , 2017 , 141, 1460-1461	5	9
34	Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , 2017 , 71, e27-e28	10.2	0

33	Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. <i>Eur Urol</i> 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. <i>European Urology</i> , 2017 , 71, e73-e75	10.2	6
32	Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. <i>Frontiers in Oncology</i> , 2017 , 7, 305	5.3	17
31	Epigenetic Modifications and Modulators in Prostate Cancer. <i>Critical Reviews in Oncogenesis</i> , 2017 , 22, 439-450	1.3	8
30	Urinary Biomarkers for Prostate Cancer. <i>Current Drug Metabolism</i> , 2017 , 18, 723-726	3.5	3
29	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. <i>Current Drug Metabolism</i> , 2017 , 18, 700-711	3.5	21
28	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , 2017 , 18, 692-699	3.5	7
27	Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. <i>Current Drug Metabolism</i> , 2017 , 18, 712-722	3.5	24
26	Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. <i>Asian Journal of Andrology</i> , 2017 ,	2.8	1
25	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. <i>European Urology</i> , 2016 , 69, 186-90	10.2	13
24	Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. <i>Archives of Pathology and Laboratory Medicine</i> , 2016 , 140, 501-2	5	10
23	Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma. <i>Histopathology</i> , 2016 , 68, 850-7	7.3	30
22	Prostate cancer: from Gleason scoring to prognostic grade grouping. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 433-40	3.5	16
21	Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy. <i>Molecular Diagnosis and Therapy</i> , 2016 , 20, 111-7	4.5	57
20	Metabolic phenotype of bladder cancer. <i>Cancer Treatment Reviews</i> , 2016 , 45, 46-57	14.4	117
19	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , 2016 , 70, e72-4	10.2	5
18	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. <i>Eur Urol</i> 2015;68:542-3. <i>European Urology</i> , 2016 , 70, e69-70	10.2	
17	Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report. <i>Human Pathology</i> , 2015 , 46, 1040-4	3.7	5
16	Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Gröberg, Lars Egevad. Tracking the Origin of Metastatic Prostate Cancer. <i>Eur Urol</i> 2015;67:819-22. <i>European Urology</i> , 2015 , 68, e134-5	10.2	3

15	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015 , 34, 765-73	9.6	28
14	Re: epithelial-to-mesenchymal transition in renal neoplasms. <i>European Urology</i> , 2015 , 68, 736-7	10.2	8
13	Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterations. <i>Histopathology</i> , 2015 , 67, 20-38	7.3	16
12	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. <i>Cancer Treatment Reviews</i> , 2015 , 41, 614-22	14.4	18
11	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 303-9	2.8	12
10	Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , 2015 , 1, FSO15	2.7	39
9	Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview. <i>Current Drug Targets</i> , 2015 , 16, 96-102	3	5
8	Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 630-7	11.2	25
7	Total submission of lymphadenectomy tissues removed during radical prostatectomy for prostate cancer: possible clinical significance of large-format histology. <i>Human Pathology</i> , 2014 , 45, 2059-62	3.7	7
6	Seminal vesicle intraepithelial neoplasia versus basal cell hyperplasia in a seminal vesicle. <i>European Urology</i> , 2014 , 66, 623-7	10.2	15
5	Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections. <i>Human Pathology</i> , 2014 , 45, 745-52	3.7	6
4	Words of wisdom. Re: Antibody-drug conjugates targeting prostate-specific membrane antigen. <i>European Urology</i> , 2014 , 66, 1190-3	10.2	5
3	Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. <i>Pathology</i> , 2014 , 46, 653-5	1.6	10
2	Clear cell renal cell carcinoma (ccRCC) with hemangioblastoma-like features: a previously unreported pattern of ccRCC with possible clinical significance. <i>European Urology</i> , 2014 , 66, 806-10	10.2	15
1	Nuclear changes in the normal-looking columnar epithelium adjacent to and distant from prostatic intraepithelial neoplasia and prostate cancer. Morphometric analysis in whole-mount sections. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000 , 437, 625-34	5.1	31